Tonix Pharmaceuticals recently announces the results of a interim analysis of phase three study for the drug candidate TNX102SL in fibromyalgia. CEO Seth Lederman visits New to the Street to discuss it further.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/channel/UCceRKKS0QUfXlKUPBoxdTHQ
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list